Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/30903
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorITO, Juliana Tiyaki
dc.contributor.authorCERVILHA, Daniela Aparecida de Brito
dc.contributor.authorLOURENCO, Juliana Dias
dc.contributor.authorGONCALVES, Natalia Gomes
dc.contributor.authorVOLPINI, Rildo Aparecido
dc.contributor.authorCALDINI, Elia Garcia
dc.contributor.authorLANDMAN, Gilles
dc.contributor.authorLIN, Chin Jia
dc.contributor.authorVELOSA, Ana Paula Pereira
dc.contributor.authorTEODORO, Walcy Paganelli Rosolia
dc.contributor.authorTIBERIO, Iolanda de Fatima Lopes Calvo
dc.contributor.authorMAUAD, Thais
dc.contributor.authorMARTINS, Milton de Arruda
dc.contributor.authorMACCHIONE, Mariangela
dc.contributor.authorLOPES, Fernanda Degobbi Tenorio Quirino dos Santos
dc.date.accessioned2019-02-21T17:27:38Z-
dc.date.available2019-02-21T17:27:38Z-
dc.date.issued2019
dc.identifier.citationPLOS ONE, v.14, n.1, article ID e0209351, 19p, 2019
dc.identifier.issn1932-6203
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/30903-
dc.description.abstractBackground The imbalance between pro- and anti-inflammatory immune responses plays a pivotal role in chronic obstructive pulmonary disease (COPD) development and progression. To clarify the pathophysiological mechanisms of this disease, we performed a temporal analysis of immune response-mediated inflammatory progression in a cigarette smoke (CS)-induced mouse model with a focus on the balance between Th17 and Treg responses. Methods C57BL/6 mice were exposed to CS for 1, 3 or 6 months to induce COPD, and the control groups were maintained under filtered air conditions for the same time intervals. We then performed functional (respiratory mechanics) and structural (alveolar enlargement) analyses. We also quantified the NF-kappa B, TNF-alpha, CD4, CD8, CD20, IL-17, IL-6, FOXP3, IL-10, or TGF-beta positive cells in peribronchovascular areas and assessed FOXP3 and IL-10 expression through double-label immunofluorescence. Additionally, we evaluated the gene expression of NF-kappa B and TNF in bronchiolar epithelial cells. Results Our CS-induced COPD model exhibited an increased proinflammatory immune response (increased expression of the NF-kappa B, TNF-alpha, CD4, CD8, CD20, IL-17, and IL-6 markers) with a concomitantly decreased anti-inflammatory immune response (FOXP3, IL-10, and TGF-beta markers) compared with the control mice. These changes in the immune responses were associated with increased alveolar enlargement and impaired lung function starting on the first month and third month of CS exposure, respectively, compared with the control mice. Conclusion Our results showed that the microenvironmental stimuli produced by the release of cyto-kines during COPD progression lead to a Th17/Treg imbalance.eng
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo [2014/15819-8 - FDTQSL]
dc.description.sponsorshipCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (demanda social - JTI)
dc.description.sponsorshipFundacao Faculdade de Medicina through the Programa de Fomento as Atividades de Pesquisa
dc.language.isoeng
dc.publisherPUBLIC LIBRARY SCIENCEeng
dc.relation.ispartofPlos One
dc.rightsopenAccesseng
dc.subject.otherobstructive pulmonary-diseaseeng
dc.subject.othermouse modeleng
dc.subject.otherlungeng
dc.subject.othercellseng
dc.subject.otherexpressioneng
dc.subject.otherinflammationeng
dc.subject.otherresponseseng
dc.subject.otherimmunityeng
dc.subject.otherth17eng
dc.subject.otherregeng
dc.titleTh17/Treg imbalance in COPD progression: A temporal analysis using a CS-induced modeleng
dc.typearticleeng
dc.rights.holderCopyright PUBLIC LIBRARY SCIENCEeng
dc.identifier.doi10.1371/journal.pone.0209351
dc.identifier.pmid30629626
dc.subject.wosMultidisciplinary Scienceseng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalLANDMAN, Gilles:Univ Fed Sao Paulo, Dept Pathol, Multipurpose Lab Mol Pathol, Sao Paulo, Brazil
hcfmusp.description.articlenumbere0209351
hcfmusp.description.issue1
hcfmusp.description.volume14
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000455483000023
hcfmusp.origem.id2-s2.0-85059807010
hcfmusp.publisher.citySAN FRANCISCOeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceBaraldo S, 2008, EUR RESPIR J, V31, P486, DOI 10.1183/09031936.00000608eng
hcfmusp.relation.referenceBarcelo B, 2008, EUR RESPIR J, V31, P555, DOI 10.1183/09031936.00010407eng
hcfmusp.relation.referenceBrereton CF, 2011, J IMMUNOL, V186, P5896, DOI 10.4049/jimmunol.1003789eng
hcfmusp.relation.referenceBrusselle GG, 2011, LANCET, V378, P1015, DOI 10.1016/S0140-6736(11)60988-4eng
hcfmusp.relation.referenceChen K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020333eng
hcfmusp.relation.referenceChen WJ, 2003, CYTOKINE GROWTH F R, V14, P85, DOI 10.1016/S1359-6101(03)00003-0eng
hcfmusp.relation.referenceChu SY, 2011, INT IMMUNOPHARMACOL, V11, P1780, DOI 10.1016/j.intimp.2011.06.010eng
hcfmusp.relation.referenceDi Stefano A, 2009, CLIN EXP IMMUNOL, V157, P316, DOI 10.1111/j.1365-2249.2009.03965.xeng
hcfmusp.relation.referenceDuan MC, 2016, INFLAMMATION, V39, P1334, DOI 10.1007/s10753-016-0365-8eng
hcfmusp.relation.referenceEppert BL, 2013, J IMMUNOL, V190, P1331, DOI 10.4049/jimmunol.1202442eng
hcfmusp.relation.referenceFuke S, 2004, AM J RESP CELL MOL, V31, P405, DOI 10.1165/rcmb.2004.0131OCeng
hcfmusp.relation.referenceGOLD, 2018, GLOBAL STRATEGY DIAGeng
hcfmusp.relation.referenceGomes RFM, 2000, J APPL PHYSIOL, V89, P908eng
hcfmusp.relation.referenceGosman MME, 2006, EUR RESPIR J, V27, P60, DOI 10.1183/09031936.06.00007005eng
hcfmusp.relation.referenceHANTOS Z, 1992, J APPL PHYSIOL, V72, P168eng
hcfmusp.relation.referenceHiemstra PS, 2015, EUR RESPIR J, V45, P1150, DOI 10.1183/09031936.00141514eng
hcfmusp.relation.referenceHizume DC, 2012, RESP PHYSIOL NEUROBI, V181, P167, DOI 10.1016/j.resp.2012.03.005eng
hcfmusp.relation.referenceHogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158eng
hcfmusp.relation.referenceJin Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111044eng
hcfmusp.relation.referenceKimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391eng
hcfmusp.relation.referenceKurimoto E, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-5eng
hcfmusp.relation.referenceLe Rouzic O, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02434-2016eng
hcfmusp.relation.referenceLi HJ, 2015, AM J MED SCI, V349, P392, DOI 10.1097/MAJ.0000000000000447eng
hcfmusp.relation.referenceLivak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262eng
hcfmusp.relation.referenceMARGRAF LR, 1991, AM REV RESPIR DIS, V143, P391eng
hcfmusp.relation.referenceMathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442eng
hcfmusp.relation.referencePabst R, 2002, J ALLERGY CLIN IMMUN, V110, P209, DOI 10.1067/mai.2002.126836eng
hcfmusp.relation.referenceRahman MS, 2005, CLIN IMMUNOL, V115, P268, DOI 10.1016/j.clin.2005.01.014eng
hcfmusp.relation.referenceRoos AB, 2015, AM J RESP CRIT CARE, V192, P428, DOI 10.1164/rccm.201409-1689OCeng
hcfmusp.relation.referenceSales DS, 2017, COPD, V14, P533, DOI 10.1080/15412555.2017.1346069eng
hcfmusp.relation.referenceShaykhiev R, 2013, GERONTOLOGY, V59, P481, DOI 10.1159/000354173eng
hcfmusp.relation.referenceSinden NJ, 2010, THORAX, V65, P930, DOI 10.1136/thx.2009.130260eng
hcfmusp.relation.referenceSmolonska J, 2009, AM J RESP CRIT CARE, V180, P618, DOI 10.1164/rccm.200905-0722OCeng
hcfmusp.relation.referenceSmyth LJC, 2007, CHEST, V132, P156, DOI 10.1378/chest.07-0083eng
hcfmusp.relation.referenceToledo AC, 2012, EUR RESPIR J, V39, P254, DOI 10.1183/09031936.00003411eng
hcfmusp.relation.referenceToumpanakis D, 2010, AM J RESP CRIT CARE, V182, P1129, DOI 10.1164/rccm.201001-0116OCeng
hcfmusp.relation.referenceTsoumakidou M, 2011, CURR DRUG TARGETS, V12, P450, DOI 10.2174/138945011794751546eng
hcfmusp.relation.referencevan der Strate BWA, 2006, AM J RESP CRIT CARE, V173, P751, DOI 10.1164/rccm.200504-594OCeng
hcfmusp.relation.referenceWang HY, 2015, CLIN RESPIR J, V9, P330, DOI 10.1111/crj.12147eng
hcfmusp.relation.referenceWang HY, 2012, INT IMMUNOPHARMACOL, V14, P504, DOI 10.1016/j.intimp.2012.09.011eng
hcfmusp.relation.referenceWeaver CT, 2009, NAT REV IMMUNOL, V9, P883, DOI 10.1038/nri2660eng
hcfmusp.relation.referenceWEIBEL ER, 1963, LAB INVEST, V12, P131eng
hcfmusp.relation.referenceZhu XH, 2009, J IMMUNOL, V182, P3270, DOI 10.4049/jimmunol.0802622eng
dc.description.indexMEDLINEeng
hcfmusp.citation.scopus34-
hcfmusp.scopus.lastupdate2024-03-29-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - FM/MPT
Departamento de Patologia - FM/MPT

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/02
LIM/02 - Laboratório de Anatomia Médico-Cirúrgica

Artigos e Materiais de Revistas Científicas - LIM/05
LIM/05 - Laboratório de Poluição Atmosférica Experimental

Artigos e Materiais de Revistas Científicas - LIM/12
LIM/12 - Laboratório de Pesquisa Básica em Doenças Renais

Artigos e Materiais de Revistas Científicas - LIM/17
LIM/17 - Laboratório de Investigação em Reumatologia

Artigos e Materiais de Revistas Científicas - LIM/20
LIM/20 - Laboratório de Terapêutica Experimental

Artigos e Materiais de Revistas Científicas - LIM/22
LIM/22 - Laboratório de Patolologia Cardiovascular

Artigos e Materiais de Revistas Científicas - LIM/59
LIM/59 - Laboratório de Biologia Celular

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_ITO_Th17Treg_imbalance_in_COPD_progression_A_temporal_analysis_2019.PDFpublishedVersion (English)4.3 MBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.